565 related articles for article (PubMed ID: 22789538)
1. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ; Poortinga G; Sanij E; Hein N; Peck A; Cullinane C; Wall M; Cluse L; Drygin D; Anderes K; Huser N; Proffitt C; Bliesath J; Haddach M; Schwaebe MK; Ryckman DM; Rice WG; Schmitt C; Lowe SW; Johnstone RW; Pearson RB; McArthur GA; Hannan RD
Cancer Cell; 2012 Jul; 22(1):51-65. PubMed ID: 22789538
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling.
Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
Oncotarget; 2016 Aug; 7(31):49800-49818. PubMed ID: 27391441
[TBL] [Abstract][Full Text] [Related]
3. Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders.
Calo E; Gu B; Bowen ME; Aryan F; Zalc A; Liang J; Flynn RA; Swigut T; Chang HY; Attardi LD; Wysocka J
Nature; 2018 Feb; 554(7690):112-117. PubMed ID: 29364875
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia.
Ye Q; Pang S; Zhang W; Guo X; Wang J; Zhang Y; Liu Y; Wu X; Jiang F
Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):476-484. PubMed ID: 28062495
[TBL] [Abstract][Full Text] [Related]
5. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.
Drygin D; Lin A; Bliesath J; Ho CB; O'Brien SE; Proffitt C; Omori M; Haddach M; Schwaebe MK; Siddiqui-Jain A; Streiner N; Quin JE; Sanij E; Bywater MJ; Hannan RD; Ryckman D; Anderes K; Rice WG
Cancer Res; 2011 Feb; 71(4):1418-30. PubMed ID: 21159662
[TBL] [Abstract][Full Text] [Related]
6. The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy.
Woods SJ; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2015 Jul; 1849(7):821-9. PubMed ID: 25464032
[TBL] [Abstract][Full Text] [Related]
7. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
8. Targeting the nucleolus for cancer intervention.
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Biochim Biophys Acta; 2014 Jun; 1842(6):802-16. PubMed ID: 24389329
[TBL] [Abstract][Full Text] [Related]
9. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
10. p53 induces a survival transcriptional response after nucleolar stress.
Liao H; Gaur A; Mauvais C; Denicourt C
Mol Biol Cell; 2021 Oct; 32(20):ar3. PubMed ID: 34319761
[TBL] [Abstract][Full Text] [Related]
11. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis.
Negi SS; Brown P
Oncotarget; 2015 Jul; 6(20):18094-104. PubMed ID: 26061708
[TBL] [Abstract][Full Text] [Related]
12. PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway.
Chen H; Duo Y; Hu B; Wang Z; Zhang F; Tsai H; Zhang J; Zhou L; Wang L; Wang X; Huang L
Oncotarget; 2016 Nov; 7(48):78747-78763. PubMed ID: 27729611
[TBL] [Abstract][Full Text] [Related]
13. Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers.
Udugama M; Sanij E; Voon HPJ; Son J; Hii L; Henson JD; Chan FL; Chang FTM; Liu Y; Pearson RB; Kalitsis P; Mann JR; Collas P; Hannan RD; Wong LH
Proc Natl Acad Sci U S A; 2018 May; 115(18):4737-4742. PubMed ID: 29669917
[TBL] [Abstract][Full Text] [Related]
14. Targeting the nucleolus for cancer-specific activation of p53.
Drygin D; O'Brien SE; Hannan RD; McArthur GA; Von Hoff DD
Drug Discov Today; 2014 Mar; 19(3):259-65. PubMed ID: 23993916
[TBL] [Abstract][Full Text] [Related]
15. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
16. Acrolein preferentially damages nucleolus eliciting ribosomal stress and apoptosis in human cancer cells.
Wang HT; Chen TY; Weng CW; Yang CH; Tang MS
Oncotarget; 2016 Dec; 7(49):80450-80464. PubMed ID: 27741518
[TBL] [Abstract][Full Text] [Related]
17. The nuclear mitotic apparatus protein NuMA controls rDNA transcription and mediates the nucleolar stress response in a p53-independent manner.
Jayaraman S; Chittiboyina S; Bai Y; Abad PC; Vidi PA; Stauffacher CV; Lelièvre SA
Nucleic Acids Res; 2017 Nov; 45(20):11725-11742. PubMed ID: 28981686
[TBL] [Abstract][Full Text] [Related]
18. p53 represses ribosomal gene transcription.
Budde A; Grummt I
Oncogene; 1999 Jan; 18(4):1119-24. PubMed ID: 10023689
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
Hein N; Cameron DP; Hannan KM; Nguyen NN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
Blood; 2017 May; 129(21):2882-2895. PubMed ID: 28283481
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer.
Bursać S; Prodan Y; Pullen N; Bartek J; Volarević S
Trends Cancer; 2021 Jan; 7(1):57-76. PubMed ID: 32948502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
